[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566767":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":28,"locations":38,"responsibleParty":53,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Our Lady of the Lake Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"EGFR Positive Lung Cancer",null,"Subjects diagnosed with EGFR positive lung cancer",[13,14],"Other: blood draw","Other: Gene sequencing",{"label":16,"type":10,"description":17,"interventionNames":18},"Healthy Subjects","Subjects who do not have a cancer diagnosis",[13,14],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"blood draw","A 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.",[9,16],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Gene sequencing","Subjects will have their DNA sequenced within and around the EGFR gene.",[9,16],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Cynthia Knox, MBA","CONTACT","225-765-3344","Cynthia.Knox@fmolhs.org",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Christine LeBoeuf, DNP","225-763-5956","Christine.Leboeuf@fmolhs.org",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":10},"Our Lady of the Lake Regional Medical Center","RECRUITING","Baton Rouge","Louisiana","70808","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-91.18747,30.44332,{"lat":51,"lon":50},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Leslie Son","Director of Clinical Research","100566767","utilizing-long-read-sequencing-to-investigate-the-egfr-landscape-of-egfr-positive-lung-cancer-patients-100566767",false,"NCT06659458","Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients","EGFR Lung Canc","Inclusion Criteria:\n\n* 18-100 years old\n* Biologically born female\n* Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)\n* No cancer diagnosis (Arm 2-health control)\n\nExclusion Criteria:\n\n* less than 18 years of age\n* Biologically born male\n* Incarcerated at the time of participation",true,"FEMALE","18 Years","100 Years",{"count":69,"type":70},20,"ESTIMATED","OBSERVATIONAL","EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.",[74,75],"Lung Cancer - Non Small Cell","EGFR Exon 19 Deletion Mutation",[77,78],"Lung cancer","EGFR gene","2025-03-17",{"date":81,"type":82},"2025-03-20","ACTUAL",{"date":84,"type":82},"2025-01-01",{"date":86,"type":70},"2025-12-31",{"name":5,"class":6},1]